You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs
SBC: FIMBRION THERAPEUTICS INC Topic: NIAIDOvermillion women suffer from urinary tract infectionsUTIannually in the U Sandof these patients will suffer from recurrent infectionsincluding approximatelypatientsmostly womenwho will suffer from highly recurrentgreater thanepisodes per yearUTIAntimicrobial treatment of UTIs has resulted in increasing antimicrobial resistance among uropathogenic EcoliUPECto first line empiric therapiessuch as tr ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of an improved, low-cost polio vaccine (Ir-IPV)
SBC: BIOLOGICAL MIMETICS, INC. Topic: NIAIDAbstractAfter decades of effortglobal campaigns to eradicate poliovirus are nearing completionEradiation of wild type PVhas been certified and PVand PVmay be eradicated in the next few yearsMany organizations and countries have collaborated in these efforts and are to be congratulated for their dedication and persistenceThe oral polio vaccineOPVhas been the workhorse of mass vaccination efforts be ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Rapid Molecular Detection of Tuberculosis without PCR amplification
SBC: SCANOGEN INC. Topic: NIAIDProject Summary TuberculosisTBis a major global burden that killsmillion people every yearTB mostly affects developing countriesbut the rise of multi drug and extensively drug resistant strains is a global threatIn order to control and eradicate this diseaseit is imperative to have adequate tools to detect active TB in limited resource settings and point of carePOCsettingswhich is where most TB pa ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
In Vivo Editing for Hemophilia Gene Therapy
SBC: GENVEC, INC. Topic: 100Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDPROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: 102Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Regulators of NaV Channels Novel Anti Allodynic Drug Candidates
SBC: Regulonix Topic: 102PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a common prevalence and potentially dose limiting side effect of many cancer chemotherapy drug treatment regimens Clinically CIPN presents with pain that is burning shooting or electric shock like The increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Vaccine for Walnut and Pecan Allergies
SBC: PROFECTUS BIOSCIENCES, INC. Topic: NIAIDAbstract IgE mediated food allergies have become a major public health concern now estimated to affect of children under years old and of adults in the US Approximately emergency hospital visits are caused from allergic reactions to foods annually with at least fatalities resulting from anaphylaxis The overall economic cost of food allergies in the US is estimated at $ ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ITK TXK Inhibitors as Oral Immunotherapeutic Drugs for Psoriasis
SBC: CONFLUENCE LIFE SCIENCES, INC. Topic: NIAMSPsoriasis is a devastating autoimmune disease that manifests itself in the form of patchy inflammatory skin lesions that can appear anywhere throughout the body resulting in tremendous physical pain and discomfort This chronic disease can also cause arthritic joints and have a profound impact on a patient s psychological well being In psoriatic lesions the detection of increased numbers of T c ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a Numerical Model for Microbubble Enhanced Treatment in HIFU Therapy
SBC: DYNAFLOW, INC. Topic: 102Development of a Numerical Model for Microbubble Enhanced Treatment in HIFU Therapy High Intensity Focused Ultrasound HIFU is currently utilized in many modern therapeutic and surgical medical applications such as for tissue ablation in the treatment of cancer and benign prostatic hyperplasia New HIFU research frontier has moved toward the treatment of deep seated solid tumors such as in liv ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health